PARTNER WITH USTo fight disease

It takes over $2.5 billion and an average of 12 years to bring a drug

to market from pre-clinical discovery to Phase III trial approval.

95% of drugs in Phase I fail to reach the market

Conversant Bio was founded because the drug discovery research model was broken.

NEW MINDSET

Companies want drugs to “fail faster.”

They focus on speed and cost with breakthrough therapy designations.

But the lack of well-characterized, appropriately consented human

According to the National Cancer Institute, “the lack of highly characterized biospecimens is the

#1 barrier to the advancement

of new therapies.”

biospecimens continues to hamper the development of new drugs.

Because Patients Are Waiting…™

Conversant Bio addresses these problems in a new way and one mantra guides us:

Our projects begin with the researcher.

How does Conversant Bio help advance pre-clinical disease research?

We spend time working with our clients to better understand the goals of their research and utilize our extensive tissue collection network to obtain specimens meeting their specific inclusion/exclusion criteria.

Once the project scope is defined, we manage all aspects of the biospecimen procurement process.

Through our network of sites, we manage IRB application and approval, employ and train study coordinators, review and monitor all patient consent and data collection processes, build project specific collection kits, and provide biospecimens to researchers.

In all, we provide a high quality, end-to-end service for biospecimen procurement and storage for researchers.

To date, we have been a valued partner on over 3,000 unique

projects in disease research processing more than 150,000biospecimens.

We are actively involved in 175research projects.

What makes partnering with us different?

Because of our vast experience working with hospitals and outpatient clinics, we have developed turnkey solutions that

integrate seamlessly into your workflow.

Our studies fit into your workflow.

What makes partnering with us different?

Patients want to help.

With over 15,000 patients and a 94% consent rate, we have seen

overwhelming patient support and participation in our patient studies. Patients understand the need for earlier diagnostics and better treatments. All specimens are specimens are collected during existing procedures meaning there are no additional risks to patients.

What makes partnering with us different?

Glad to be here.

Conversant Bio has an educated and responsive site development team because we believe that reliable partnerships are essential to groundbreaking research anddrug discovery. Our team is available to discuss study opportunities that fit your current workflow.

To learn more about partnering with us, visit us at www.conversantbio.com/join-our-study

Because patients are waiting…™

FFPE blocks, blood, bone marrow aspirates, and/or tissues biospecimens are needed in research today!